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ess: ggudmund@landspSummary Patients with chronic obstructive pulmonary disease (COPD) often
report anxiety, depression and poor health status, not least if they experience
repeated hospitalisations due to acute exacerbations. The aim of this study was to
analyse the interrelationships between health status, anxiety, depression and
physical status in COPD patients being discharged after hospitalisation. This was a
prospective study of 416 patients in five university hospitals in each of the Nordic
countries. Data included demographic information, lung function and co-morbidity.
The Hospital Anxiety and Depression Scale and St. George’s Respiratory Ques-
tionnaire (SGRQ) were applied to all patients. Both anxiety and depression were
common among these patients. Anxiety was more common in women than in men
(47% vs. 34%, P ¼ 0:009) and current smokers had a higher prevalence of both
anxiety (54% vs. 37%) and depression (43% vs. 23%) than non-smokers (Po0:01). In
general, the studied COPD patients had poor health status, especially those with
anxiety, depression or both. Psychological status was independently related to all
dimensions of SGRQ. Higher GOLD stages were significantly associated with
increasing impairment in health status. In conclusion this multicentre study showed
that anxiety and depression are common in patients with COPD, and, furthermore,
that patients with psychological disorders have poor health status. Screening forElsevier Ltd. All rights reserved.
36876; fax: +354 5436568.
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G. Gudmundsson et al.88depression and anxiety may help to identify patients with poor quality of life and an
urgent need for intervention in order to improve their health status.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is
associated with intermittent exacerbations char-
acterised by acute deterioration in the symptoms of
chronic dyspnoea, cough and sputum production.
These acute exacerbations are the main cause for
hospitalisation in COPD patients and they are also
associated with deterioration in health status and
lung function.1,2 Health status is a very important
outcome variable. To evaluate health status valu-
able questionnaires have been developed that are
used mainly for research purposes on groups.3 This
has been done in epidemiological studies and in
studies on medications and in evaluating the
efficacy of new drugs4–6 including large trials with
inhaled corticosteroids and long-acting anticholi-
nergic medications.6–8 Other factors are also
important for the well-being of the COPD patient,
including psychological status. Depression has been
described with increased frequency in patients with
COPD.9 Anxiety is also important in patients with
chronic diseases, especially if the disease can be
life threatening as is COPD.10 Anxiety and depres-
sion can be evaluated with a questionnaire that is
short and easy to administer.11 A study on patients
with obstructive lung diseases receiving emergency
care found that those with anxiety and depression
were at much higher risk of hospitalisation or
relapse 1 month later.12 There is limited informa-
tion on the interrelationships between the mea-
sures of health status, anxiety and depression, and
physical status. Such knowledge could potentially
enable better individual care for patients with
COPD.
The aim of this study was to analyse simulta-
neously in a large prospective Nordic multicentre
setting health status, anxiety, depression, physical
status and their interrelationships before discharge
after hospitalisation for COPD exacerbation.Materials and methods
This is a prospective study of patients hospitalised
with acute exacerbations of obstructive airway
disease in five university hospitals in the Nordic
countries. The departments included were: The
Department of Respiratory Medicine and Allergol-
ogy, Akademiska sjukhuset, Uppsala, Sweden; TheDepartment of Thoracic Medicine, Haukeland Uni-
versity Hospital, Bergen, Norway; The Department
of Respiratory Medicine, Tampere University Hospi-
tal, Tampere, Finland; The Department of Respira-
tory Medicine, Vifilstadir University Hospital,
Gardabaer, Iceland and The Department of Respira-
tory Medicine, Hvidovre Hospital, Copenhagen
Denmark.
Consecutive patients from each of the partici-
pating hospitals were included provided that they
had been admitted with acute exacerbations of
obstructive lung disease (asthma, chronic bronchi-
tis, chronic obstructive bronchitis or emphysema)
during the year 2000–2001. In the following analysis
all patients with asthma were excluded and
reported are only data from those fulfilling criteria
for COPD according to the Global Initiative for
Chronic Obstructive Pulmonary Disease
(www.GOLDCOPD.com) stage 1 or higher.2
The following data were collected at discharge
from the respective pulmonary departments:1. Questionnaire that included information on
smoking history, type of living and family
situation (living at home, assisted at home,
nursing home, with spouse, alone or with others)
in addition to educational level.2. Spirometry, body weight and height. Predicted
values for forced expiratory volume in 1 s (FEV1)
and forced vital capacity (FVC) were calculated
based on the European Coal and Steel Union
reference values.133. Health status was assessed using the disease-
specific St. George’s Respiratory Questionnaire
(SGRQ). It has three components: symptoms,
activity and impact, in addition to the total
score.8 The
’ ’
symptoms’’ score measures distress
caused by respiratory symptoms,
’ ’
activity’’
measures the effect of disturbance on the
mobility and physical activity and
’ ’
impact’’
quantifies the psycho-social impact of the dis-
ease. Higher scores indicate worse health status.
Anxiety and depression were evaluated with the
Hospital Anxiety and Depression Scale (HADS).11
It is self-reported and has been used extensively
to screen psychiatric morbidity and has high
validity when it is used as a screening instrument
for psychiatric morbidity in outpatients.14–16 It is
composed of two parts, one with seven ques-
tions that are related to anxiety and another
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sion. A score of 8 or greater on either part was
used as the cut-off point for diagnosing anxiety
and depression, respectively.114. From the patient records, information was
collected on treatment during the hospitalisa-
tion and at discharge, including long-term
oxygen therapy. Assessment of co-morbidity
was based on the diagnosis used by the treating
physician. Diabetes mellitus was considered to
be present if medications were used for dia-
betes. Hypertension, ischemic heart disease or
atrial fibrillation were considered to be present
when diagnosed by the attending physican and
when the patient was using appropriate medica-
tions.10
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Analysis was carried out using Stata 8.0 (Stata
Corporation, College Station, Texas). The w2-test,
t-test and one-way analysis of variation were used
in the univariable analyses, whilst multiple linear
regression was used in the multiple variable
analyses. SGRQ scores were analysed as a contin-
uous variable and then checked for normality. In
order to detect heterogeneity between the hospi-
tals the regression estimates were also calculated
by hospital and then combined, using random
effect meta-analysis. A P-value of o0.05 was
considered statistically significant.0
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Figure 1 Staging of COPD in men and women according
to GOLD criteria.Results
A total of 416 consecutive patients with COPD were
enrolled in the study. The demographics of theTable 1 Characteristics of patients included in the stud
All
Number 416
Age (years) 69.4710.4
Smokers (%) 25.8
Pack years smoking 33.7723.9
College education (%) 30.7
Living alone (%) 52.1
FEV1 (% of predicted) 38.5718.2
FVC (% of predicted) 61.7720.3
LTOT (%) 23.6
Cardiovascular diseases (%) 45.0
Diabetes (%) 10.6
FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity;study patients are shown in Table 1. Of those
admitted, one-fourth were current smokers but
most of the patients in the study had an extensive
smoking history in the past. Women had signifi-
cantly lower life-time tobacco exposure compared
with men. Furthermore, women were more likely
to be living alone than men.Lung function, oxygen use and co-morbid
conditions
Spirometry at discharge was performed in 386 of
the patients. The mean FEV1 was low (38.5% of
predicted value) suggesting significant disease.
Figure 1 shows the distribution of the patients
according to the GOLD classification. Most of the
patients were in stages III and IV. There was a non-
significant trend that the men had more severe
COPD than women (P ¼ 0:07). The use of long-termy (mean71 SD, or as %).
Males Females P-value
205 211
71.079.4 67.8711.2 0.001
23.6 28.0 0.32
38.9727.0 28.8719.2 o0.0001
33.3 28.1 0.25
37.6 66.2 o0.0001
36.4716.2 40.5719.7 0.01
58.7717.8 64.5722.1 0.002
24.4 22.8 0.69
48.3 41.7 0.17
10.2 10.9 0.82
LTOT: long-term oxygen therapy.
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morbidities were common, with nearly half of the
patients being diagnosed with cardiovascular dis-
ease and 10% having diabetes mellitus. Further
details of the study patients are given in Table 1.Anxiety, depression and relationship
with demographic factors
Almost half of the study population suffered from
anxiety and/or depression as measured by the HAD
scale. Anxiety was significantly more common in
women than in men (Fig. 2). Both anxiety and
depression were more common in current smokers
compared with non-smokers (Po0:001) while no
significant relationship was found between psycho-
logical status and age, education, living condi-
tions, lung function, LTOT or somatic co-morbidity
(Table 2).0
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Figure 2 Psychological co-morbidity in men and women.
Table 2 Demographics and psychological disorders (mea
None Anxiety on
Number 202 81
Women (%) 47.0 56.8
Age (years) 70.0710.7 67.979.4
Smokers (%) 19.4 23.5
Pack years smoking 33.3723.4 34.9721.4
College education (%) 31.8 35.8
Living alone (%) 49.2 56.8
FEV1 (% of predicted) 39.6718.4 38.4719.0
FVC (% of predicted) 61.1720.5 64.1720.0
LTOT (%) 21.3 23.5
CV diseases (%) 41.1 49.4
Diabetes (%) 10.4 8.6
FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity;Health status
The mean total score on the SGRQ was 58,
suggesting overall poor health among these se-
verely affected COPD patients in the study. COPD
patients with anxiety, depression or both had
significantly higher scores in all domains and the
total score of the SGRQ, suggesting a worse health
status than those who did not suffer from psychia-
tric co-morbidity (Table 3).Effects of psychological condition on
health condition
Lung function and psychological status both have a
large impact on health status as measured by the
SGRQ (Table 4). A significant impairment in health
status was seen with decreasing FEV1 for all
domains except symptoms. Depression alone or
anxiety with depression had clinically significant
effects on all domains and anxiety alone had
effects on all domains except symptoms. The
effects were substantial, i.e. up to 14.8 points.
More severe COPD, as indicated by higher GOLD
stages, was significantly associated with increasing
impairment in health status. In contrast, anxiety
and depression were reported in similar frequency
regardless of the severity of COPD (Table 5).
There was no significant difference between
the study centres in the association between
psychological status and health status (P for
heterogeneity ¼ 0.88, 0.83, 0.93 and 0.98 for
symptom, activity, impact and total score, respec-
tively).n and 1 SD or %).
ly Depression only Anxiety and depression
31 79
38.7 62.0
72.376.6 67.9711.3
23.3 43.0
38.0735.1 31.4722.9
12.9 31.6
50.0 48.7
36.6715.9 39.2716.9
59.5713.1 62.1721.1
35.5 27.8
48.4 53.2
16.1 10.1
LTOT: long-term oxygen therapy; CV: cardiovascular.
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Table 4 Relationship between lung function and psychological and health status.
SGRQ components Symptoms
estimate* (95% CI)
Activity estimate
(95% CI)
Impact estimate
(95% CI)
Total estimate
(95% CI)
FEV1 (% pred)** 0.59 (1.74, 0.57) 4.10 (5.33, 2.87) 2.29 (3.42, 1.16) 2.59 (3.56, 1.62)
Anxiety 3.32 (1.89, 8.53) 5.77 (0.26, 11.3) 9.49 (4.37, 14.6) 7.09 (2.68, 11.5)
Depression 6.04 (1.71, 13.8) 5.06 (3.21, 13.3) 14.8 (7.24, 22.4) 10.3 (3.83, 16.8)
Anxiety and
Depression
6.02 (0.68, 11.4) 12.0 (6.25, 17.7) 13.2 (8.02, 18.5) 11.9 (7.39, 16.33)
*Estimates are regression coefficients derived from multiple linear regression.
**Calculated per 10% unit.
Adjusted for country, smoking, educational level, living partner and co-morbidity (cardiovascular disease and diabetes).
Table 5 Health and psychological status in different GOLD stages.
GOLD stages Stage I and II mild
and moderate
Stage III severe Stage IV very severe P-value
Number 95 120 180
Psychological status (%)
Anxiety 42.4 39.6 41.3 0.92
Depression 31.5 25.0 30.8 0.50
Anxiety and/or
depression
48.9 46.8 50.6 0.83
Health status SGRQ points
Symptoms 61.9719.6 62.6719.7 68.0717.8 0.01
Activity 58.0724.0 64.1721.8 74.5717.5 o0.001
Impact 41.7721.3 43.2719.2 51.6718.1 o0.001
Total 51.4718.6 54.7717.2 63.0714.9 o0.001
Table 3 Health status and psychological condition.
All None Anxiety Depression Anxiety and depression
Number 383 199 78 30 76
SGRQ points
Symptoms 61.1720.2 68.0716.0 69.7717.4 69.0717.2
Activity 62.7723.6 69.3718.8 70.9719.3 74.7716.8
Impact 40.3719.1 52.1718.5 55.9717.8 53.6717.9
Total 58 52.3717.8 61.8715.0 64.1714.0 64.2714.6
Depression, anxiety and health status in COPD 91Discussion
The main findings of our prospective multicentre
study of a large group of COPD patients were that
patients being discharged after hospitalisation for
acute exacerbation had a high prevalence of
anxiety and depression and also a poor health
status. Women and current smokers were morelikely to suffer from more significant anxiety or
depression. There was a close relation between
health status and psychological condition among
these severely affected COPD patients who were
close to being discharged from the hospital. Their
health status may be expected to improve with
increasing time from recovery after their exacer-
bation17 but we are not aware of studies on the
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health status and psychological condition.
The prevalence of poor health status, anxiety and
depression found are in accordance with those of
some other studies. In a recent study by van Manen
it was shown that the risk for depression in stable
COPD patients from general practice was 2.5 times
greater in patients with severe COPD (FEV1o50% of
predicted) compared to controls.18 Living alone,
respiratory symptoms and physical impairment were
also significantly associated with the risk for
depression. In the COPD group, as a whole, 21.6%
were depressed compared to 17.5% in the control
group. In another study by the same author, where
the prevalence of co-morbidity in patients with
chronic airway obstruction was studied, depression
was found to be more common in the study group
than among the controls.9 Heart disease and
diabetes were not more common in the patients
with chronic airway obstruction than in the control
group. A study from Japan on 218 male patients
with COPD of differing severity showed higher
scores on SGRQ (worse health status) with increas-
ing severity of disease19; and also a correlation
between the HAD scale and SGRQ. In another study,
patients with COPD reported anxiety with increased
frequency and this correlated with severity of
disease.20 In a recent study, GOLD stages II and
higher, marked a dramatic worsening of health
status as measured by SGRQ, but psychological
status was not analysed simultaneously.21
Multiple studies have shown how various inter-
ventions such as medications can improve health
status.3–7,22 In such studies the change in the SGRQ
score of 4 units is regarded as clinically significant.3
In our study the effects that anxiety and depression
have on the SGRQ scores were striking or up to 12
units. This is a figure that is much higher than most
medications have.5,7 Based on our descriptive
epidemiological study we are tempted to speculate
whether improving psychological status can by
itself lead to improved health status, even inde-
pendent of changes in pulmonary status. Vice versa
would be equally interesting. In future studies it
could be valuable to include both measures of
psychological status as well as health status when
evaluating different treatment outcomes. Studies
are lacking regarding the primary effect of medica-
tions such as anxiolytics, antidepressants and
inhaled corticosteroids on both health status and
psychological status among patients with COPD.23
From a clinical point of view, our study under-
lines how important it is to identify those COPD
patients who suffer anxiety and depression at
discharge after an acute exacerbation and to pay
attention to these commonly encountered com-plaints. This study shows that special attention
needs to be put on females with COPD and current
smokers. The HAD scale is a simple and effective
way to screen patients for anxiety and depression.
It requires only a short time to apply and analyse
and is well standardised, all of which makes it
attractive for this purpose.11,14–16 Further studies
should be conducted evaluating the effect of
treatment of anxiety and depression and also to
analyse whether simple screening tests such as the
HAD scale can be used to select those that could
benefit from specific therapy based on future
randomised trials.Acknowledgements
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